AGYTF (Allergy Therapeutics) 3-Month Share Buyback Ratio: 0.00% (As of Dec. 2025 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AGYTF Allergy Therapeutics PLC AGYTF
24 GF Score
Price $0.15
GF Value $0.03
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Allergy Therapeutics 3-Month Share Buyback Ratio?

Allergy Therapeutics AGYTF +7.14% 24 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus rates AGYTF with a GF Score™ of 24/100 and a GF Value™ of $0.03 (Significantly Overvalued). The stock has 7 warning signs investors should review.

3-Month Share Buyback Ratio only apply to companies whose reporting frequency is 3 months.

AGYTF
24GF Score
Allergy Therapeutics PLC AGYTF
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a 3-Month Share Buyback Ratio of 0.00 mean?
Allergy Therapeutics (AGYTF) has a 3-Month Share Buyback Ratio of 0.00 as of Dec. 2025. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Allergy Therapeutics and its competitors.
Is Allergy Therapeutics' 3-Month Share Buyback Ratio too high?
Allergy Therapeutics' current 3-Month Share Buyback Ratio is 0.00. Overall, Allergy Therapeutics has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Allergy Therapeutics' 3-Month Share Buyback Ratio compare to ZTS and UTHR?
Allergy Therapeutics' 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Drug Manufacturers company?
A good 3-Month Share Buyback Ratio depends on the Drug Manufacturers industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Allergy Therapeutics and its competitors. Allergy Therapeutics's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allergy Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Allergy Therapeutics (AGYTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.03, compared to a current price of $0.15 — trading 400% above its estimated fair value. The current 3-Month Share Buyback Ratio is 0.00. Allergy Therapeutics' overall GF Score™ is 24/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Allergy Therapeutics (AGYTF), the current 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Allergy Therapeutics (AGYTF) Overvalued in 2026?

Based on GuruFocus' analysis, Allergy Therapeutics stock appears to be overvalued. The current stock price of $0.15 is trading 400% above its estimated GF Value™ of $0.03. GuruFocus considers Allergy Therapeutics to be Significantly Overvalued.

Key valuation signals for AGYTF:

  • 3-Month Share Buyback Ratio: 0.00
  • GF Value™: $0.03 vs. price of $0.15 (400% above fair value)
  • GF Score™: 24/100 with 7 warning signs

No single metric tells the full story. See the AGYTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Allergy Therapeutics Business Description

Other Exchanges AGY:UKHHU:Germany
Address Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).
24GF Score

Get the complete analysis for AGYTF

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price
$0.03
GF Value